←Back to Expert Scholars
Translational Medicine / 转化医学Regulatory T Cells, Treg Cell Therapy
Jeffrey Bluestone
PhD
🏢Sonoma Biotherapeutics / UCSF🌐USA
President and CEO, Sonoma Biotherapeutics
135
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Jeffrey Bluestone is a foundational figure in anti-CTLA-4 and Treg biology and now leads Sonoma Biotherapeutics developing engineered Treg cell therapies. His career has spanned basic tolerance mechanisms and clinical translation of Treg-based therapies for autoimmunity and transplant.
Share:
🧪Research Fields 研究领域
engineered Treg therapy
anti-CTLA-4 discovery
Treg adoptive transfer
tolerance induction
CAR-Treg
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Jeffrey Bluestone 的研究动态
Follow Jeffrey Bluestone's research updates
留下邮箱，当我们发布与 Jeffrey Bluestone（Sonoma Biotherapeutics / UCSF）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment